Early-stage resectable non-small cell lung cancer in Hungary
Pathology and Oncology Research · 2025
DOI: 10.3389/pore.2025.1612152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology and Oncology Research, 2025. Verfasst von Gabriella Gálffy und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncopulmonology, Pulmonology Center of the Reformed Church in Hungary, Törökbálint, Hungary. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study provides a comprehensive analysis of early-stage resectable non-small cell lung cancer (NSCLC) in Hungary, investigating incidence rates, demographic trends, treatment patterns and survival outcomes. We used data from the National Health Insurance Fund (NHIF) spanning 2013–2022, and we analyzed 6,571 patients with available NSCLC histology and no metastasis, who underwent curative surgery within 6 months of diagnosis, and evaluated epidemiological trends and the use of neoadjuvant and adjuvant therapies. For the efficacy analysis, we narrowed the patient cohort to 5,494 patients diagnosed and treated between 2013 and 2019 with at least three-year follow-up data. Key endpoints included overall survival (OS) and disease-free survival (DFS), inferred via time to first subsequent therapy (TFST). Our results revealed a gradual decline in early-stage resectable NSCLC diagnoses, with a significant drop in 2020, likely linked to COVID-19 restrictions. Older age groups (66–75 years) represented a growing proportion of cases, reflecting shifting demographic trends. Among patients with EGFR mutations receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, OS significantly improved compared to those not receiving EGFR-TKI therapy, who are assumed to have wild-type EGFR status (HR = 0.58 (95% CI: 0.47–0.72), p < 0.0001). These findings underscore the importance of early detection, comprehensive biomarker testing and targeted therapies in improving outcomes for resectable NSCLC patients. Future studies with extended follow-up and integration of broader clinical data, including staging and patient comorbidities, are warranted to optimize therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncopulmonology, Pulmonology Center of the Reformed Church in Hungary, Törökbálint, Hungary.
- AstraZeneca Ltd., Budapest, Hungary.
- MedicalScan Ltd., Budapest, Hungary.
- Department of Surgical and Molecular Pathology, National Institute of Oncology, Budapest, Hungary.
- National Korányi Institute of Pulmonology, Budapest, Hungary.
- Department of Thoracic Surgery, Semmelweis University, Budapest, Hungary.
Zitieren
APA
Gálffy, G., Hécz, R., Bujdosó, R., Gáspár, E., Korompay, R., Hoffer, J., Szécsényi, S., Blasszauer, C., Reibl, D., Tóth, E., Bogos, K., Agócs, L., Rényi-Vámos, F., & Mórocz, É. (2025). Early-stage resectable non-small cell lung cancer in Hungary. Pathology and Oncology Research. https://doi.org/10.3389/pore.2025.1612152
Vancouver
Gálffy G, Hécz R, Bujdosó R, Gáspár E, Korompay R, Hoffer J, et al. Early-stage resectable non-small cell lung cancer in Hungary. Pathology and Oncology Research. 2025. doi:10.3389/pore.2025.1612152
BibTeX
@article{Glffy2025,
author = {Gálffy, Gabriella and Hécz, Réka and Bujdosó, Réka and Gáspár, Eszter and Korompay, Réka and Hoffer, Judit and Szécsényi, Szilvia and Blasszauer, Celia and Reibl, Dániel and Tóth, Erika and Bogos, Krisztina and Agócs, László and Rényi-Vámos, Ferenc and Mórocz, Éva},
title = {Early-stage resectable non-small cell lung cancer in Hungary},
journal = {Pathology and Oncology Research},
year = {2025},
doi = {10.3389/pore.2025.1612152}
}
EUVIMED